{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:17:28Z","timestamp":1767143848977,"version":"build-2238731810"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40263-015-0254-y","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T01:32:14Z","timestamp":1435714334000},"page":"511-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Oxycodone\/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome"],"prefix":"10.1007","volume":"29","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,2]]},"reference":[{"key":"254_CR1","unstructured":"International Restless Legs Syndrome Study Group. 2012 Revised IRLSSG diagnostic criteria for RLS. http:\/\/irlssg.org . Accessed 27 Jan 2015."},{"issue":"2","key":"254_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.17925\/ENR.2013.08.02.97","volume":"8","author":"A Kalloo","year":"2013","unstructured":"Kalloo A, Gamaldo CE, Kwan AB, et al. The impact of restless legs syndrome\/Willis\u2013Ekbom disorder on quality of life. Eur Neurol Rev. 2013;8(2):97\u2013104.","journal-title":"Eur Neurol Rev."},{"key":"254_CR3","first-page":"S207","volume":"18","author":"RE Salas","year":"2012","unstructured":"Salas RE, Kwan AB. The real burden of restless legs syndrome: clinical and economic outcomes. Am J Manag Care. 2012;18:S207\u201312.","journal-title":"Am J Manag Care."},{"issue":"4","key":"254_CR4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s11325-011-0606-x","volume":"16","author":"P Yeh","year":"2012","unstructured":"Yeh P, Walters AS, Tsuang JW. Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath. 2012;16(4):987\u20131007.","journal-title":"Sleep Breath."},{"issue":"4","key":"254_CR5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.smrv.2011.05.002","volume":"16","author":"MM Ohayon","year":"2012","unstructured":"Ohayon MM, O\u2019Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16(4):283\u201395.","journal-title":"Sleep Med Rev."},{"issue":"4","key":"254_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1155\/2013\/585439","volume":"26","author":"R Jones","year":"2013","unstructured":"Jones R, Cavanna AE. The neurobiology and treatment of restless legs syndrome. Behav Neurol. 2013;26(4):283\u201392.","journal-title":"Behav Neurol."},{"issue":"11","key":"254_CR7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11940-014-0317-2","volume":"16","author":"WG Ondo","year":"2014","unstructured":"Ondo WG. Restless legs syndrome: pathophysiology and treatment. Curr Treat Options Neurol. 2014;16(11):317. doi: 10.1007\/s11940-014-0317-2 .","journal-title":"Curr Treat Options Neurol."},{"issue":"2","key":"254_CR8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.smrv.2013.03.004","volume":"18","author":"M Hornyak","year":"2014","unstructured":"Hornyak M, Scholz H, Kohnen R, et al. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev. 2014;18(2):153\u201364.","journal-title":"Sleep Med Rev."},{"issue":"5","key":"254_CR9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.7861\/clinmedicine.14-5-520","volume":"14","author":"L Klingelhoefer","year":"2014","unstructured":"Klingelhoefer L, Cova I, Gupta S, et al. A review of current treatment strategies for restless legs syndrome (Willis-Ekbom disease). Clin Med. 2014;14(5):520\u20134.","journal-title":"Clin Med."},{"key":"254_CR10","doi-asserted-by":"crossref","unstructured":"Rios Romenets S, Postuma RB. Treatment of restless legs syndrome. Curr Treat Options Neurol. 2013;15(4):396\u2013409.","DOI":"10.1007\/s11940-013-0241-x"},{"issue":"4","key":"254_CR11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s13311-012-0139-4","volume":"9","author":"MJ Buchfuhrer","year":"2012","unstructured":"Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome. Neurotherapeutics. 2012;9(4):776\u201390.","journal-title":"Neurotherapeutics."},{"key":"254_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13311-013-0247-9","volume":"11","author":"CL Comella","year":"2014","unstructured":"Comella CL. Treatment of restless legs syndrome. Neurotherapeutics. 2014;11:177\u201387.","journal-title":"Neurotherapeutics."},{"issue":"7","key":"254_CR13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH. The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675\u201384.","journal-title":"Sleep Med."},{"key":"254_CR14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1468-1331.2012.03853.x","volume":"19","author":"D Garcia-Borreguero","year":"2012","unstructured":"Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19:1385\u201396.","journal-title":"Eur J Neurol."},{"key":"254_CR15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/postgradmedj-2012-131634","volume":"89","author":"K Nagandla","year":"2013","unstructured":"Nagandla K, De S. Restless legs syndrome: pathophysiology and modern management. Postgrad Med J. 2013;89:402\u201310.","journal-title":"Postgrad Med J."},{"issue":"8","key":"254_CR16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5665\/sleep.1986","volume":"35","author":"RN Aurora","year":"2012","unstructured":"Aurora RN, Kristo DA, Bista SR. The treatment of restless legs syndrome and periodic limb movement disorder in adults\u2014an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses. Sleep. 2012;35(8):1039\u201362.","journal-title":"Sleep."},{"key":"254_CR17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2377-11-28","volume":"11","author":"D Garcia-Borreguero","year":"2011","unstructured":"Garcia-Borreguero D, Stillman P, Benes H. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol. 2011;11:28. doi: 10.1186\/471-2377-11-28 .","journal-title":"BMC Neurol."},{"key":"254_CR18","unstructured":"Mundipharma International Ltd. Mundipharma receives positive European Commission decision on Targin\u00ae (oxycodone\/naloxone) for the treatment of restless legs syndrome [press release]. 2015. http:\/\/www.mundipharma.com . Accessed 17 Mar 2015."},{"key":"254_CR19","unstructured":"European Medicines Agency. Oxynal-Targin and associated names. International non-proprietary name\/active substance: oxycodone hydrochloride\/naloxone hydrochloride. European public assessment report. 2014. http:\/\/www.ema.europa.eu . Accessed 17 Mar 2015."},{"key":"254_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40122-014-0026-2","volume":"3","author":"AZ DePriest","year":"2014","unstructured":"DePriest AZ, Miller K. Oxycodone\/naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther. 2014;3:1\u201315.","journal-title":"Pain Ther."},{"key":"254_CR21","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00520-014-2435-5","volume":"23","author":"SH Ahmedzai","year":"2015","unstructured":"Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015;23:823\u201330.","journal-title":"Support Care Cancer."},{"issue":"3","key":"254_CR22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-014-0177-9","volume":"74","author":"CB Burness","year":"2014","unstructured":"Burness CB, Keating GM. Oxycodone\/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs. 2014;74(3):353\u201375.","journal-title":"Drugs."},{"key":"254_CR23","unstructured":"Mundipharma Pharmaceuticals Ltd. Targin\u00ae 5\u00a0mg\/2.5\u00a0mg, 10\u00a0mg\/5\u00a0mg, 20\u00a0mg\/10\u00a0mg and 40\u00a0mg\/20\u00a0mg prolonged release tablets. Irish summary of product characteristics. http:\/\/www.medicines.ie . Accessed 29 Apr 2015."},{"issue":"12","key":"254_CR24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1474-4422(13)70239-4","volume":"12","author":"C Trenkwalder","year":"2013","unstructured":"Trenkwalder C, Benes H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141\u201350.","journal-title":"Lancet Neurol."},{"key":"254_CR25","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.jns.2013.07.572","volume":"333","author":"R Kohnen","year":"2013","unstructured":"Kohnen R, Benes H, Grote L, et al. Oxycodone\/naloxone prolonged-release has positive quality of life outcomes in patients with severe RLS\u2014results of a 1-year study [abstract no. 2183]. J Neurol Sci. 2013;333:e86.","journal-title":"J Neurol Sci."},{"key":"254_CR26","unstructured":"Benes H, Hornyak M, Hopp M, et al. Prolonged-release oxycodone\/naloxone improves sleep quantity and adequacy over 1\u00a0year in patients with severe restless legs syndrome [abstract no. PF135]. 15th World Congress on Pain, Buenos Aires; 6\u201311 Oct 2014."}],"updated-by":[{"DOI":"10.1007\/s40263-015-0274-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0254-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0254-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0254-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T17:45:56Z","timestamp":1566927956000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0254-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0254-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}